For example, etanercept blocks the activation of the TNF‐α pathway and inhibits the inflammatory cascade by preventing the binding of TNF‐α to its receptor (2.5 mg systematical administration before modeling + 2.5 mg intraperitoneal dose 3 days later, or 5.0 μg h−1 for 7 days by long‐term infusion into the scala tympani using an osmotic pump).[55] Gevokizumab binds to IL‐1β and blocks the induced inflammatory response to protect against hearing loss.[56] Anakinra can competitively bind to the IL‐1 receptor and block the binding, thus effectively reducing hearing loss.[57]. Here, IL1B is linked to hearing loss disorder.